Results for tag: "Elaprase"

The Elaprase market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat lysosomal storage disorders, such as Hunter Syndrome. These drugs are used to replace the missing enzyme in the body, which helps to break down certain molecules. The Elaprase market is a relatively small market, but it is growing due to the increasing prevalence of lysosomal storage disorders. The Elaprase market is dominated by a few large pharmaceutical companies, such as Shire, Sanofi, and Pfizer. These companies have developed drugs that are approved by the FDA for the treatment of Hunter Syndrome. Other companies, such as BioMarin and Ultragenyx, are also developing drugs for the treatment of lysosomal storage disorders. Show Less Read more